Gallium-68 edotreotide PDUFA Date (Lantheus Holdings)
FDA PDUFA decision date for Gallium-68 edotreotide is March 29, 2026. Developed by Lantheus Holdings. Indication: Somatostatin receptor+ neuroendocrine tumors (PET imaging). Current status: Verifying.
Indication
Somatostatin receptor+ neuroendocrine tumors (PET imaging)
Regulatory details
- Company: Lantheus Holdings
- Therapeutic area: Oncology / Nuclear Medicine
- Application type: NDA
- Review type: Standard
- PDUFA date: 2026-03-29
- Outcome: Pending